SCHEMBL5484651

SCHEMBL5484651

CN1CCN(C(=O)NCc2ccc(N3CCOCC3)cc2)CC1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.67
▸ MEN1 O00255 2/20 0.67
▸ TP53 P04637 1/20 0.56
▸ NOS3 P29474 1/20 0.56
▸ NOS1 P29475 1/20 0.56
▸ ACE2 Q9BYF1 1/20 0.55
▸ CASP3 P42574 1/20 0.54
▸ NPC1 O15118 2/20 0.52
▸ GFER P55789 1/20 0.52
▸ LMNA P02545 3/20 0.51
▸ ERCC1 P07992 1/20 0.50
▸ ERCC4 Q92889 1/20 0.50
▸ HTT P42858 1/20 0.50
▸ RECQL P46063 1/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ MLLT1 Q03111 1/20 0.48
▸ HRH3 Q9Y5N1 1/20 0.48
▸ GAA P10253 1/20 0.48
▸ RAB9A P51151 1/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28466660 0.80 MEN1 (0.78) KMT2AMEN1TP53NOS3NOS1
SCHEMBL5465071 0.80 MEN1 (1.00) KMT2AMEN1LMNAHRH3RAB9A
SCHEMBL5474021 0.79 MEN1 (0.76) KMT2AMEN1TP53NPC1LMNA
SCHEMBL848854 0.79 MEN1 (0.76) KMT2AMEN1LMNAHRH3KDM4E
SCHEMBL5466273 0.79 KMT2A (0.76) KMT2AMEN1NPC1LMNASMN1; SMN2
SCHEMBL5471150 0.79 MEN1 (0.75) KMT2AMEN1TP53LMNAHTT
SCHEMBL2755879 0.79 ERCC1 (0.58) KMT2ACASP3NPC1ERCC1ERCC4
SCHEMBL4979260 0.78 EPHX2 (0.54) KMT2AACE2CASP3NPC1ERCC1
SCHEMBL4102507 0.77 KMT2A (0.66) KMT2AMEN1TP53ACE2NPC1
SCHEMBL26155519 0.77 USP2 (0.56) KMT2AACE2NPC1ERCC1ERCC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070249618-A1 Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression ASTRAZENECA AB (SE) 2007-10-25 — — US disclosed
US-20070249618-A1 Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression ASTRAZENECA AB (SE) 2007-10-25 — — US disclosed
US-20070249618-A1 Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression ASTRAZENECA AB (SE) 2007-10-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249618-A1 Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression HRH3, HRH1, HRH4 KMT2A 323/4885MEN1 3623/4885TP53 4618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback